Literature DB >> 1694318

Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506.

G Eiras1, O Imventarza, N Murase, Y Ueda, S Todo, T Starzl, R J Duquesnoy, A Zeevi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1694318      PMCID： PMC2974268          DOI： 10.1097/00007890-199006000-00029

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  14 in total

1.  Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats.

Authors:  T Ochiai; K Nakajima; M Nagata; S Hori; T Asano; K Isono
Journal:  Transplantation       Date:  1987-12       Impact factor: 4.939

2.  Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine.

Authors:  N Murase; S Todo; P H Lee; H S Lai; F Chapman; M A Nalesnik; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

3.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

4.  Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids.

Authors:  S Todo; A J Demetris; Y Ueda; O Imventarza; K Okuda; A Casavilla; S Cemaj; A Ghalab; V Mazzaferro; B S Rhoe
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

5.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

6.  Effect of FK-506 on human mixed lymphocyte reaction in vitro.

Authors:  T Kino; N Inamura; F Sakai; K Nakahara; T Goto; M Okuhara; M Kohsaka; H Aoki; T Ochiai
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes.

Authors:  A Sanghvi; V Warty; A Zeevi; W Diven; R Duquesnoy; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

Review 8.  Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.

Authors:  B D Kahan
Journal:  Transplantation       Date:  1985-11       Impact factor: 4.939

9.  IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION.

Authors:  A Zeevi; R Duquesnoy; G Eiras; S Todo; L Makowka; T Starzl
Journal:  Surg Res Commun       Date:  1987

10.  Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

Authors:  S Todo; Y Ueda; J A Demetris; O Imventarza; M Nalesnik; R Venkataramanan; L Makowka; T E Starzl
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982
View more
  3 in total

Review 1.  Interpreting tacrolimus concentrations during pregnancy and postpartum.

Authors:  Mary F Hebert; Songmao Zheng; Karen Hays; Danny D Shen; Connie L Davis; Jason G Umans; Menachem Miodovnik; Kenneth E Thummel; Thomas R Easterling
Journal:  Transplantation       Date:  2013-04-15       Impact factor: 4.939

2.  Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells.

Authors:  K Tamura; J Woo; M T Bakri; A W Thomson
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

3.  Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo.

Authors:  Dana E Orange; Nathalie E Blachere; John Fak; Salina Parveen; Mayu O Frank; Margo Herre; Suyan Tian; Sebastien Monette; Robert B Darnell
Journal:  Elife       Date:  2013-02-05       Impact factor: 8.140
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.